Stryker Launches Mako RPS to Expand Robotic Knee Surgery Portfolio

SYK launches Mako RPS, expanding into handheld robotics for total knee replacement and broadening access to robotic-assisted orthopedic procedures.

Zacks Investment Research • Jul 17, 2026

Stryker expands Mako robotics portfolio with full market release of Mako RPS

New handheld robotic technology expands the Mako platform and brings Mako robotic-assisted knee replacement to a new segment of the orthopaedic market Stryker announced the U.S. commercial launch of Mako RPS (Robotic Power System) for total knee replacement procedures. The launch introduces Mako Handheld Robotics, expanding the Mako portfolio beyond robotic-arm assisted surgery.

PRNewsWire • Jul 16, 2026

Booking, Alphabet, and 7 Other Stocks to Buy Ahead of Earnings

Booking Holdings, Alphabet, and six other companies have underperformed their sectors despite improving earnings expectations, setting up potential upside during second-quarter earnings season.

Barrons • Jul 15, 2026

Stryker: The Market Is Overreacting To One Disrupted Quarter

Stryker remains a high-quality MedTech compounder despite a rare Q1 miss driven by a temporary cyber disruption. Q1 weakness was not demand-driven; full-year guidance is unchanged and end-market demand remains healthy. Current valuation reflects temporary disruption, offering a more attractive entry into SYK, though the stock is not cheap.

Seeking Alpha • Jul 9, 2026

Stryker: Medtech On Sale, Benefiting From Industry Growth

Stryker Corporation offers a compelling medtech investment, benefiting from robust industry growth and an innovation-led strategy. SYK trades at a 13% discount to fair value, with a forward P/E of 20.1 versus a 10-year average of 25.6. Consensus expects SYK's adjusted diluted EPS to compound at 11.2% annually through 2028, supporting high single-digit dividend growth.

Seeking Alpha • Jul 8, 2026

ICUI vs. SYK: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical - Products sector might want to consider either ICU Medical (ICUI) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Jul 8, 2026

Beyond Automotive: Healthcare Automation Drives the Next Leg for Robotics ETFs

Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.

Zacks Investment Research • Jul 8, 2026

Buy these quality, low-stress stocks for the summer, says Jefferies

Markets have become more volatile as investors debate whether big tech companies are getting enough return on their AI spending. The S&P 500 momentum index has outperformed the wider market by more than 70% since 2024, close to levels seen during the 1990s dot-com era.

CNBC • Jul 7, 2026

Stryker: The Reshaped Product Portfolio Will Drive Growth

Stryker is a Dividend Aristocrat with 32 years of increases, robust cash flow, and a strong M&A-driven growth strategy. SYK's Q1 2026 results were impacted by a cybersecurity incident, but management maintained full-year guidance and expects normalization. The stock trades at ~21x 2026E EPS, below its 5-year average, suggesting undervaluation despite recent share price declines.

Seeking Alpha • Jul 2, 2026

Stryker to announce second quarter 2026 financial results

Portage, Michigan, July 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, July 30, 2026, to discuss its second quarter 2026 financial results.

GlobeNewsWire • Jul 1, 2026